DelveInsight report forecasts rapid growth in antibody-mediated rejection market

The antibody-mediated rejection (AMR) market is set for solid expansion through 2034, driven by rising transplant volumes, improved diagnostics, and a wave of late-stage therapies, according to a new report from DelveInsight. The USA remains the largest market, accounting for around 55,000 transplant cases in 2024, with numbers expected to climb steadily.

Several leading drugmakers, including US biotech Biogen (Nasdaq: BIIB), Sweden’s Hansa Biopharma (STO: HNSA), France’s Sanofi (Euronext: SAN), Belgium’s argenx (Nasdaq: ARGX), and UK-based AstraZeneca (LSE: AZN), are advancing next-generation AMR candidates. Chief among them are Biogen’s Felzartamab, Hansa’s Imlifidase, Sanofi’s Riliprubart, argenx’s Efgartigimod PH20 SC, and AstraZeneca’s (LSE AZN) ALXN2030.

Felzartamab, originally developed by MorphoSys and now part of Biogen’s portfolio, continues to show disease-modifying potential in late AMR, backed by positive Phase II data. Biogen launched its global Phase III TRANSCEND trial in March 2025. Sanofi’s Riliprubart, a C1s inhibitor, received orphan designation from the US regulator in June 2025, while Hansa’s Imlifidase, an IgG-cleaving enzyme, is approaching Phase III readouts in the USA and Europe.